These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 4644697)

  • 1. Modification of the effects of 9 -tetrahydrocannabinol by phenobarbital pretreatment in mice.
    Fujimoto JM
    Toxicol Appl Pharmacol; 1972 Dec; 23(4):623-34. PubMed ID: 4644697
    [No Abstract]   [Full Text] [Related]  

  • 2. A study of the development of tolerance to an anticonvulsant effect of delta9-tetrahydrocannabinol and cannabidiol.
    Karler R; Cely W; Turkanis SA
    Res Commun Chem Pathol Pharmacol; 1974 Sep; 9(1):23-39. PubMed ID: 4438826
    [No Abstract]   [Full Text] [Related]  

  • 3. Anticonvulsant properties of cannabidiol.
    Turkanis SA; Cely W; Olsen DM; Karler R
    Res Commun Chem Pathol Pharmacol; 1974 Jun; 8(2):231-46. PubMed ID: 4850602
    [No Abstract]   [Full Text] [Related]  

  • 4. The interaction of 9 -tetrahydrocannabinol pretreatment with various sedative-hypnotic drugs.
    Sofia RD; Knobloch LC
    Psychopharmacologia; 1973 May; 30(2):185-94. PubMed ID: 4711375
    [No Abstract]   [Full Text] [Related]  

  • 5. Anticonvulsant activities of delta-8 and delta-9 tetrahydrocannabinol and uridine.
    Dwivedi C; Harbison RD
    Toxicol Appl Pharmacol; 1975 Mar; 31(3):452-8. PubMed ID: 1145630
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of subchronic treatment with (-) 8 -trans-tetrahydrocannabinol ( 8 -THC) on food intake, body temperature, hexobarbital sleeping time and hexobarbital elimination in rats.
    Rating D; Broermann I; Honecker H; Kluwe S; Coper H
    Psychopharmacologia; 1972; 27(4):349-57. PubMed ID: 4648618
    [No Abstract]   [Full Text] [Related]  

  • 7. Modification of delta9-THC-actions by cannabinol and cannabidiol in the rat.
    Fernandes M; Schabarek A; Coper H; Hill R
    Psychopharmacologia; 1974; 38(4):329-38. PubMed ID: 4473791
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of acute and chronic pretreatment with delta1-tetrahydrocannabinol on motor impairment by ethanol in the rat.
    Kalant H; LeBlanc AE
    Can J Physiol Pharmacol; 1974 Apr; 52(2):291-7. PubMed ID: 4838189
    [No Abstract]   [Full Text] [Related]  

  • 9. Anticonvulsant activity of delta9-tetrahydrocannabinol compared with three other drugs.
    Sofia RD; Solomon TA; Barry H
    Eur J Pharmacol; 1976 Jan; 35(1):7-16. PubMed ID: 1253828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cannabichromene and delta 9-tetrahydrocannabinol: interactions relative to lethality, hypothermia and hexobarbital hypnosis.
    Hatoum NS; Davis WM; Elsohly MA; Turner CE
    Gen Pharmacol; 1981; 12(5):357-62. PubMed ID: 6269951
    [No Abstract]   [Full Text] [Related]  

  • 11. Interactions of chronic and acute 1 -tetrahydrocannabinol pretreatment with zoxazolamine and barbiturates.
    Sofia RD
    Res Commun Chem Pathol Pharmacol; 1973 Jan; 5(1):91-8. PubMed ID: 4686112
    [No Abstract]   [Full Text] [Related]  

  • 12. Acute antiepileptic effects of 9-tetrahydrocannabinol in rats with kindled seizures.
    Corcoran ME; McCaughran JA; Wada JA
    Exp Neurol; 1973 Aug; 40(2):471-83. PubMed ID: 4354188
    [No Abstract]   [Full Text] [Related]  

  • 13. Anticonvulsant activity of delta9-tetrahydrocannabilol and its 11-hydroxy and 8alpha, 11-dihydroxy metabolites in the frog.
    Karler R; Cely W; Turkanis SA
    Res Commun Chem Pathol Pharmacol; 1974 Nov; 9(3):441-52. PubMed ID: 4548551
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacokinetic and pharmacodynamic tolerance of a new anticonvulsant agent (3-sulfamoylmethyl-1,2-benzisoxazole) compared to phenobarbital, diphenylhydantoin and carbamazepine in rats.
    Masuda Y; Utsui Y; Shiraishi Y; Karasawa T; Yoshida K; Shimizu M
    Arch Int Pharmacodyn Ther; 1979 Jul; 240(1):79-89. PubMed ID: 507999
    [No Abstract]   [Full Text] [Related]  

  • 15. The influence of lynestrenol on the rate of metabolism of phenobarbital, phenytoin and hexobarbital in mice.
    Rümke CL; Noordhoek J
    Eur J Pharmacol; 1969 May; 6(2):163-8. PubMed ID: 5796802
    [No Abstract]   [Full Text] [Related]  

  • 16. Cannabis sativa L. (marijuana). V. Pharmacological evaluation of marijuana aqueous extract and volatile oil.
    Segelman AB; Sofia RD; Segelman FP; Harakal JJ; Knobloch LC
    J Pharm Sci; 1974 Jun; 63(6):962-4. PubMed ID: 4850869
    [No Abstract]   [Full Text] [Related]  

  • 17. [Studies in mice on the effectiveness of various methods of enzyme induction with phenobarbital].
    Buzello W; Scholler KL; Schöppe B
    Arzneimittelforschung; 1973 Sep; 23(9):1337-9. PubMed ID: 4801232
    [No Abstract]   [Full Text] [Related]  

  • 18. Propylene glycol as a drug solvent in pharmacologic studies.
    Zaroslinski JF; Browne RK; Possley LH
    Toxicol Appl Pharmacol; 1971 Aug; 19(4):573-8. PubMed ID: 5132028
    [No Abstract]   [Full Text] [Related]  

  • 19. Cannabinoids and hexobarbital induced loss of righting reflexes.
    Fernandes M; Kluwe S; Coper H
    Naunyn Schmiedebergs Arch Pharmacol; 1974; 283(4):431-5. PubMed ID: 4278425
    [No Abstract]   [Full Text] [Related]  

  • 20. Metabolism of delta1-tetrahydrocannabinol by rats tolerant to cannabis.
    Siemens AJ; Kalant H
    Can J Physiol Pharmacol; 1974 Dec; 52(6):1154-66. PubMed ID: 4451887
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.